Flywire Corp Q4 FY2025 earnings call

Mike Massaro discussed the company's progress since IPO, strategic focus on embedded receivables platform, 3 operating priorities (accelerating product and platform innovation, building scalable enterprise growth engine, accelerating internal transformation). Rob Orgel talked about go-to-market execution with deep vertical expertise, 750 net new clients in 2025, growth in education, travel, health care, B2B verticals, and improved sales productivity. Cosmin Pitigoi covered Q4 financial performance, adjusted gross profit, EBITDA margin, and 2026 guidance including revenue, margin, and capital allocation plans

Not explicitly detailed with absolute and revenue contribution % for each segment in a way to directly extract and present; need to infer but text doesn't have clear cut per segment absolute and % breakdown as asked

Full year 2026 expected 15% - 21% FX-neutral revenue growth, adjusted gross profit margin decline 200 - 300 basis points year-over-year, EBITDA margin expansion 150 - 350 basis points reaching 22.5% midpoint, GAAP net income expected to grow 3 - 4x vs 2025, Q1 2026 expected ~28% FX-neutral revenue growth and 225 basis points margin expansion

Not explicitly detailed in a bullet pointed risk discussion as per text; text doesn't have clear risk points listed as required

Q: On guidance macro assumptions in US and Australia, A: Cosmin Pitigoi said prudent approach, US visa down 30% is prudent, Australia flat visas but team winning deals.

Q: On SFS, A: Rob Orgel talked about US SFS success, 3x ARR growth, and non - Big 4 opportunity.

Q: On sales motion and bigger deals, A: Rob Orgel said growth in ARR due to targeting larger clients and full suite presentation.

Q: On M&A, A: Mike Massaro said disciplined with stock buyback and monitoring fit - profile companies.

Q: On Canada and guidance variables, A: Cosmin Pitigoi said Canada outperformed and guidance top end due to better macro and strong execution.

Q: On travel outlook, A: Cosmin Pitigoi said travel growth at or above company average, focus on sales team and Sertifi expansion.

Q: On stablecoin, A: Mike Massaro said live and testing demand.

Q: On education outside Big 4, A: Rob Orgel said share gains in Europe and Asia markets.

Q: On health care in 2026, A: Rob Orgel said Cleveland Clinic deal and pipeline expansion.

Q: On new sales booking, A: Mike Massaro said investing in go - to - market engine.

Q: On optimizing international payment flows, A: Rob Orgel said serving payer and school better by presenting local payment options